When immunoprecipitated endogenous MYCN from MYCN-amplified neuroblastoma cells was immunoblotted with a ubiquitin antibody, we found that combination therapy markedly increased MYCN ubiquitination (Fig. 3e). The gene discussed is MYCN; the disease is neuroblastoma.